Azitra Inc (AZTR) Q2 2024 Earnings Report

Azitra Inc (AZTR) reported QQ2 2024 results ending 2024-06-30 that underscore a capital‑intensive, preclinical biotechnology model with effectively no meaningful revenue and a compounding cash burn. Revenue of $7.5 thousand was insufficient to cover even current period cost of revenue ($113.9 thousand) and operating expenses ($2.6679 million), resulting in an EBITDA of approximately $(2.516) million and a net loss of $(2.631) million for the quarter. The per‑share metric reflected a negative ADS/stock value of $(2.74) for the quarter on 960,145 diluted shares. The company’s cash balance stood at $0.803 million at quarter end, with operating cash burn of $(2.101) million and a free cash flow burn of $(2.177) million, signaling an acute near‑term liquidity challenge absent additional financing.

From a year-over-year perspective, top-line revenue declined about 95.6% versus QQ2 2023 (from $172k to $7.5k), while gross profit swung from a modest profit of $70.8k in QQ2 2023 to a gross loss of $(106.4k) in QQ2 2024. Despite a still deeply negative profitability profile, some efficiency in the posted EPS trajectory is observable, with diluted EPS improving by approximately 75% year over year (from $(4.36) to $(2.74)). The quarter maintains the company’s characteristic R&D intensity, with R&D expense of $1.118 million versus a tiny revenue base, underscoring the preclinical stage and the dependency on external funding and partnerships for future value creation.

Outlook remains uncertain given the lack of explicit guidance in the release and the ongoing need for financing to sustain pipeline activities. The near‑term investment thesis hinges on: (1) continued progress in Azitra’s dermatology platform (ATR12, ATR04, ATR01) and potential partnering discussions, (2) the ability to secure non-dilutive or minimally dilutive financing to extend runway, and (3) meaningful clinical or translational milestones that could unlock collaboration or licensing value. Investors should weigh the considerable risk of continued dilution and liquidity constraints against the potential long‑term payoff if pipeline candidates advance toward clinical development and strategic partnerships materialize.